Malignant Pleural Mesothelioma Clinical Trials

7 recruiting

Malignant Pleural Mesothelioma Trials at a Glance

13 actively recruiting trials for malignant pleural mesothelioma are listed on ClinicalTrialsFinder across 6 cities in 9 countries. The largest study group is Phase 1 with 5 trials, with the heaviest enrollment activity in London, Manchester, and Cambridge. Lead sponsors running malignant pleural mesothelioma studies include Azienda USL Reggio Emilia - IRCCS, Beijing Biotech, and Asbestos Disease Research Institute.

Browse malignant pleural mesothelioma trials by phase

Treatments under study

About Malignant Pleural Mesothelioma Clinical Trials

Looking for clinical trials for Malignant Pleural Mesothelioma? There are currently 7 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Malignant Pleural Mesothelioma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Malignant Pleural Mesothelioma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 113 of 13 trials

Recruiting

Evaluation of Cell Changes in Blood and Tissue in Cancers of the Lung, Esophagus and Lung Lining

Thoracic CancersLung Cancer NOSMalignant Pleural Mesotheliomas NOS+2 more
National Cancer Institute (NCI)1,559 enrolled1 locationNCT00242723
Recruiting

Multidimensional Omics Analysis in Malignant Pleural Mesothelioma

Malignant Pleural Mesothelioma (MPM)
Azienda USL Reggio Emilia - IRCCS300 enrolled4 locationsNCT07561190
Recruiting
Phase 1Phase 2

Dual-Target MSLN/FAP CAR-NK Cells for Pleural and Peritoneal Mesothelioma

Malignant Pleural Mesotheliomas
Beijing Biotech36 enrolled1 locationNCT07510815
Recruiting
Not Applicable

Hemithoracic Irradiation With Proton Therapy in Malignant Pleural Mesothelioma

Malignant Pleural Mesothelioma
University College, London148 enrolled25 locationsNCT05655078
Recruiting
Phase 2

The IMmunotherapy Pleural 5-ALA PDT

Malignant Pleural MesotheliomaMesotheliomas Pleural
University Hospital, Lille20 enrolled1 locationNCT04400539
Recruiting
Not Applicable

Using E-Nose Technology to Measure Response to Treatment in People With Malignant Pleural Mesothelioma

Malignant Pleural Mesothelioma
Memorial Sloan Kettering Cancer Center20 enrolled7 locationsNCT06037941
Recruiting
Phase 1

A Study of NX-1607 in Adults With Advanced Malignancies

Gastric CancerNon-small Cell Lung Cancer (NSCLC)Head and Neck Squamous Cell Carcinoma+5 more
Nurix Therapeutics, Inc.345 enrolled17 locationsNCT05107674
Recruiting
Phase 1

CT-95 in Advanced Cancers Associated With Mesothelin Expression

Mesothelin-Expressing TumorsEpithelial Ovarian CancerLung Adenocarcinoma Metastatic+7 more
Context Therapeutics Inc.70 enrolled8 locationsNCT06756035
Recruiting
Phase 2

Study of Pembrolizumab Plus Chemotherapy With Lenvatinib for Malignant Pleural Mesothelioma

Malignant Pleural Mesothelioma
Hyogo Medical University25 enrolled1 locationNCT06318286
Recruiting
Not Applicable

Hemithoracic Arc Radiotherapy Post Pleural Decortication

Malignant Pleural Mesothelioma
Cairo University45 enrolled1 locationNCT06910449
Recruiting
Phase 1Phase 2

Integration of the PD-L1 Inhibitor Atezolizumab and WT1/DC Vaccination Into Platinum/Pemetrexed-based First-line Treatment for Epithelioid Malignant Pleural Mesothelioma

Malignant Pleural Mesothelioma
University Hospital, Antwerp15 enrolled3 locationsNCT05765084
Recruiting

Oncolytic Adenovirus(H101) Combined With PD-1 Inhibitors in Patients With Advanced Malignant Pleural Mesothelioma

Malignant Pleural Mesothelioma, Advanced
Tianjin Medical University Second Hospital15 enrolled1 locationNCT06031636
Recruiting
Phase 1

The first testing of TargomiRs in the human setting: dose-finding studies in patients with recurrent malignant pleural mesothelioma and non-small cell lung cancer

Malignant Pleural Mesothelioma
Asbestos Disease Research Institute30 enrolled3 locationsACTRN12614001248651